FACCHETTI, FLORIANA
FACCHETTI, FLORIANA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
2025 M.P. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide
2024 P. Toniutto, E. Falleti, S. Cmet, A. Cussigh, E. Degasperi, M.P. Anolli, D. Sambarino, F. Facchetti, M. Borghi, R. Perbellini, S. Monico, P. Lampertico
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B
2024 A. Vecchi, M. Rossi, C. Tiezzi, P. Fisicaro, S. Doselli, E.A. Gabor, A. Penna, I. Montali, C. Ceccatelli Berti, V. Reverberi, A. Montali, S.P. Fletcher, E. Degasperi, D. Sambarino, D. Laccabue, F. Facchetti, S. Schivazappa, E. Loggi, B. Coco, D. Cavallone, E. Rosselli Del Turco, M. Massari, G. Pedrazzi, G. Missale, G. Verucchi, P. Andreone, M.R. Brunetto, P. Lampertico, C. Ferrari, C. Boni
Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B
2024 B. Testoni, C. Scholtès, M. Plissonnier, A. Paturel, F. Berby, F. Facchetti, F. Villeret, E. Degasperi, B. Scott, A. Hamilton, M. Heil, P. Lampertico, M. Levrero, F. Zoulim
Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods
2024 M.P. Anolli, S.U. Renteria, E. Degasperi, M. Borghi, F. Facchetti, D. Sambarino, R. Perbellini, S. Monico, F. Ceriotti, P. Lampertico
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta
2024 E. Degasperi, C. Scholtes, B. Testoni, S.U. Renteria, M.P. Anolli, C. Charre, F. Facchetti, M. Plissonnier, D. Sambarino, R. Perbellini, S. Monico, A. Callegaro, E. García-Pras, S. Lens, M.F. Cortese, X. Forns, S. Pérez-Del-Pulgar, M. Heil, M. Levrero, F. Zoulim, P. Lampertico
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients
2021 A. Papatheodoridi, A. Chatzigeorgiou, L. Chrysavgis, P. Lembessis, A. Loglio, F. Facchetti, E. Cholongitas, M. Koutsilieris, P. Lampertico, G. Papatheodoridis
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients
2020 M. Viganò, A. Loglio, F. Cerini, E. Farina, F. Facchetti, R. Perbellini, M.G. Rumi, P. Lampertico
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs
2020 E. Degasperi, E. Galmozzi, S. Pelusi, R. D'Ambrosio, R. Soffredini, M. Borghi, R. Perbellini, F. Facchetti, M. Iavarone, A. Sangiovanni, L. Valenti, P. Lampertico
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy
2020 A. Loglio, M. Iavarone, F. Facchetti, D. Di Paolo, R. Perbellini, G. Lunghi, F. Ceriotti, C. Galli, M.T. Sandri, M. Vigano, A. Sangiovanni, M. Colombo, P. Lampertico
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide
2020 L. Roade, A. Loglio, M. Borghi, M. Riveiro-Barciela, R. Soffredini, F. Facchetti, D. di Paolo, D. Tabernero, G. Lunghi, R. Esteban, M. Buti, P. Lampertico
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
2019 B. Testoni, F. Lebossé, C. Scholtes, F. Berby, C. Miaglia, M. Subic, A. Loglio, F. Facchetti, P. Lampertico, M. Levrero, F. Zoulim
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
2019 M. Vigano, A. Loglio, S. Labanca, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, A. Tucci, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, V. Occhipinti, F. Facchetti, G. Grossi, M. Rumi, P. Lampertico
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy
2019 A. Loglio, M. Iavarone, M. Vigano, A. Orenti, F. Facchetti, I. Cortinovis, G. Lunghi, F. Ceriotti, V. Occhipinti, M. Rumi, A. Sangiovanni, M. Colombo, P. Lampertico
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
2019 A. Dodero, A. Guidetti, A. Tucci, F. Barretta, M. Novo, L. Devizzi, A. Re, A. Passi, A. Pellegrinelli, G. Pruneri, R. Miceli, A. Testi, M. Pennisi, M.C. Di Chio, P. Matteucci, C. Carniti, F. Facchetti, G. Rossi, P. Corradini
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B
2018 A. Loglio, M. Iavarone, G. Grossi, M. Viganò, M.G. Rumi, F. Facchetti, G. Lunghi, A. Sangiovanni, M. Colombo, P. Lampertico
Indeterminate cell histiocytosis/indeterminate dendritic cell tumour
2018 F. Facchetti, E. Berti, B. Zelger
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance
2018 G. Glenda, A. Loglio, F. Facchetti, B. Marta, R.M. Soffredini, E. Galmozzi, L. Giovanna, G. Anuj, P. Lampertico
Erheim-Chester disease
2018 F. Facchetti, B. Zelger, E. Berti, E.S. Jaffe